Table 3.

Treatment-related adverse events occurring at ≥10% incidence for all grades.

AEs, n (%)	Any Grade	Grades 1–2	Grade 3	Grade 4
Nausea	23 (44.2%)	22 (42.3%)	1 (1.9%)	0 (0.0%)
Fatigue	22 (42.3%)	20 (38.5%)	2 (3.8%)	0 (0.0%)
Elevated AST	21 (40.4%)	18 (34.6%)	3 (5.8%)	1 (1.9%)
Abdominal pain	20 (38.4%)	18 (34.6%)	2 (3.8%)	0 (0.0%)
Elevated ALT	18 (34.6%)	16 (30.8%)	2 (3.8%)	1 (1.9%)
Hypertension	17 (32.7%)	13 (25.0%)	4 (7.7%)	2 (3.8%)
Vomiting	16 (30.7%)	14 (26.9%)	2 (3.8%)	0 (0.0%)
Proteinuria	15 (28.8%)	13 (25.0%)	2 (3.8%)	1 (1.9%)
Thrombocytopenia	14 (26.9%)	12 (23.1%)	2 (3.8%)	1 (1.9%)
Hyperbilirubinemia	11 (21.2%)	11 (21.2)	0 (0.0%)	0 (0.0%)
Leukopenia	10 (19.2%)	8 (15.4%)	2 (3.8%)	0 (0.0%)
Decreased appetite	9 (17.3%)	8 (15.4%)	1 (1.9%)	0 (0.0%)
Hypothyroidism	8 (15.3%)	8 (15.3%)	0 (0.0%)	0 (0.0%)
Diarrhea	7 (13.4%)	6 (11.5%)	1 (1.9%)	0 (0.0%)
Pyrexia	7 (13.4%)	7 (13.4%)	0 (0.0%)	0 (0.0%)
Neutropenia	7 (13.4%)	6 (11.5%)	1 (1.9%)	0 (0.0%)
Weight decrease	5 (10.4%)	5 (10.4%)	0 (0.0%)	0 (0.0%)

ALT, alanine aminotransferase; AST, aspartate aminotransferase.